An interventional study of Targeted Temperature Management with CB240_Aurora and Standard of care Temperature treatment in Ischemic Stroke, sponsored by Azienda Usl di Bologna. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-17.
Sponsored by Azienda Usl di Bologna · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Ischemic Stroke with a site in Italy — 23 open to participants now, 29 under way, 2 of them phase 3. Ischemic Stroke · Italy.
Among the 81 studies in Ischemic Stroke with a site in Italy, this one is the 43rd largest by planned enrollment of the 50 interventional ones that give a count, is one of 11 that started in 2025, is one of 31 with no phase, reaches primary completion later than 8 of the 28 other live ones, and was the 75th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →23 of the 81 studies in Ischemic Stroke with a site in Italy are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Italy, Belgium, Germany and 3 more countries
Ages 18+
Niguarda Hospital · Sites in Italy
Ages 18+
Italian Society of Vascular and Endovascular Surgery · Sites in Italy
Ages 45–90
Corxel Pharmaceuticals · Sites in Italy, United States, Belgium and 18 more countries
Ages 18–90
University of Milano Bicocca · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 10 · Phase 4 5
First in 2000; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 22 is below the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 227 across the 50 interventional studies, 550 across the 30 observational. Of the 40 that completed or were terminated, 13 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 81 have an industry lead sponsor. The 10 most frequent:
Azienda Usl di Bologna is the lead sponsor of 44 studies on the registry; 14 are open to participants now.
Azienda Usl di Bologna has 4 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
7 of the studies in Ischemic Stroke with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06710028Fondazione Policlinico Universitario Agostino Gemelli IRCCSTrustworthy Artificial Intelligence for Improvement of Stroke Outcomes | 2026-11-30 |
| NCT07199322Fondazione Don Carlo Gnocchi ETSClinical validatiOn of an AI-based DEcision Support System for Robotic Upper Limb Rehabilitation in Patients With Stroke. A CO-AIDER Study. | 2026-12 |
| NCT04562194VesalioNeVa ONE Registry Study | 2026-12-31 |
| NCT04339699Nobles Medical Technologies II IncNobleStitch EL STITCH Trial is a PFO Comparative Trial | 2026-12-31 |
| NCT06823466University of L'AquilaAdvancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants | 2027-02-12 |
Add all 7 to your calendar (.ics) → With an account.
Among the 81 studies in Ischemic Stroke with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this interventional trial is to evaluate whether the CB240_Aurora medical device is effective for targeted temperature management in adult patients with acute ischemic stroke. The main questions it aims to answer are: Is the CB240_Aurora effective in maintaining normothermia in patients with acute ischemic stroke? Does the medical device improve clinical and radiological outcomes? Is the medical device well tolerated by patients? Researchers will compare an interventional arm, in which the CB240_Aurora measures and treats body temperature to maintain normothermia, with a control arm, in which the CB240_Aurora only measures but does not treat body temperature. Participants will wear the medical device for 72 consecutive hours in the Stroke Unit. Outcome assessments will be performed at 72 hours, 7 days, and 3 months.
Neuroprotection is a potential therapeutic strategy to complement reperfusion and prevent the progression of cerebral ischemia in patients with acute ischemic stroke. One of the most promising approaches is Targeted Temperature Management (TTM), which involves controlling body temperature to prevent fever, maintain normothermia, or induce hypothermia in order to reduce brain injury and improve clinical outcomes. While hypothermia has demonstrated clinical benefits in patients with cardiac arrest and hypoxic- schemic encephalopathy, no significant evidence currently supports its efficacy in acute stroke. Maintaining normothermia through TTM may offer similar neuroprotective benefits with fewer complications. Current guidelines for patients with intracerebral hemorrhage, subarachnoid hemorrhage, and ischemic stroke recommend maintaining body temperature between 36°C and 37.5°C, ideally using automated control systems.
In this context, Neuron Guard has developed the CB240_Aurora device, which targets cerebral temperature through the vascular anatomy of the neck to enhance heat exchange. This system has shown potential in stabilizing brain temperature while maintaining systemic normothermia and reducing systemic side effects. Its use could be extended beyond intensive care settings to broader patient populations, both for managing fever episodes and for enhancing neuroprotection.
The experimental treatment with the CB240_Aurora device is designed as a complementary approach to standard therapies, aiming to improve their effectiveness. The device will continuously monitor body temperature and deliver treatment to maintain normothermia, defined as a temperature ≥36°C and \<37°C at the time of study inclusion.
In the control group, patients will receive care according to the latest ischemic stroke treatment guidelines, including standard temperature management. In this group, the CB240_Aurora device will be used exclusively for temperature monitoring without providing active treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive targeted temperature management to maintain normothermia using the CB240\_Aurora device.
Device: Targeted Temperature Management with CB240_Aurora · Device: Standard of care Temperature treatment
CB240\_Aurora device used exclusively in temperature monitoring and control mode according to clinical standards
Device: Standard of care Temperature treatment
The proposed experimental treatment with the CB240\_Aurora device will serve as a complementary approach to standard therapies, aiming to enhance their effectiveness. The device will continuously monitor body temperature and deliver treatment to maintain normothermia, defined as a temperature ≥36°C and \<37°C at the time of study inclusion.
In the control group, patients will receive treatment according to the latest guidelines for the management of ischemic stroke, including standard body temperature management. The CB240\_Aurora device will be used exclusively in monitoring mode, without delivering any active treatment, and will be maintained for 72 consecutive hours from the time of enrollment
Duration of normothermia maintenance during the first 72 hours
Measure the duration (in hours) of maintained normothermia (between \>36°C and \<37°C) through axillary temperature monitoring during the first 72 hours.
Time frame: T0 (0 hour)T1; ( 72 hours)
Modified Rankin Scale (mRS)
Functional outcome at 3 months, defined as the Modified Rankin Scale (mRS) score ranging from 0 to 6, with higher scores indicating worse outcomes
Time frame: T2 (day 7); T3 (day 90)
National Institutes of Health Stroke Scale (NIHSS)
Clinical outcome at 7 days, defined as the National Institutes of Health Stroke Scale (NIHSS) score ranging from 0 to 42, with higher scores indicating worse outcomes
Time frame: T2 (day 7); T3 (day 90)
Change in the volume of the ischemic lesion measured by MRI
Ischemic lesion volume will be evaluated by MRI at day 7 from randomization (T0)
Time frame: T2 (day 7)
hemorrhagic transformation of the ischemic lesion at MRI
hemorrhagic transformation of the ischemic lesion at MRI
Time frame: T2 (day 7)
Incidence of adverse events (AEs) and severe AEs (SAEs) that are related to treatment.
Safety will be assessed by measuring the incidence of AEs and SAEs throughout the stimulation period and during the 3-month follow-up
Time frame: T0 (day 0); T1 (day 3); T2 (day 7); T3( day 90)
Number of patients requiring to stop treatment sessions
Time frame: from T0 (day 0); T3 (day 90)
Qualitative assessment of device tollerability (QADT)
An ad hoc questionnaire to assess the tolerability of the device (e.g., nausea, headache, palpitations, anxiety, sweating) will be administered daily during the entire hospital stay and, after discharge, at each outpatient follow-up visit. Responses will be categorized as: Response No (Better Outcome) and Response Yes (Worse Outcome).
Time frame: T2 (day 7); T3 (day 90)
Plan to share: No
Started Sep 2025 (actual). Primary completion is estimated for Sep 2026, 12 months after the start.
Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 12 months is below that.
Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda Usl di Bologna